Coumarin embryopathy after intrauterine exposure to vitamin K antagonists within the first 10 postmenstrual weeks.
Hoyer
A C
AC
Henrich
W
W
Schaefer
C
C
Spors
B
B
Czernik
C
C
D000014:Abnormalities, Drug-Induced / Q000000981:diagnostic imaging*; D000925:Anticoagulants / Q000008:administration & dosage / Q000633:toxicity*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D007091:Image Processing, Computer-Assisted; D021621:Imaging, Three-Dimensional; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D019767:Maxillofacial Abnormalities / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D010644:Phenprocoumon / Q000008:administration & dosage / Q000633:toxicity*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D016216:Ultrasonography, Prenatal; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K; D010644:Phenprocoumon